Geertruij te Kronnie

List of Publications by Year
in descending order

152 papers	6,186 citations	87888 38 h-index	76900 74 g-index
155 all docs	155 docs citations	155 times ranked	9364 citing authors

#	Article	IF	Citations
1	TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition. Leukemia, 2021, 35, 389-403.	7.2	26
2	MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia. Blood, 2021, 138, 1953-1965.	1.4	16
3	Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. Haematologica, 2020, 105, 170-181.	3.5	37
4	Nextâ€generation sequencing of PTEN mutations for monitoring minimal residual disease in Tâ€cell acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28025.	1.5	3
5	Large-scale circular RNA deregulation in T-ALL: unlocking unique ectopic expression of molecular subtypes. Blood Advances, 2020, 4, 5902-5914.	5.2	39
6	The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. Blood Advances, 2020, 4, 4052-4064.	5.2	5
7	Proâ€inflammatory cytokines favor the emergence of ETV6â€RUNX1â€positive preâ€leukemic cells in a model of mesenchymal niche. British Journal of Haematology, 2020, 190, 262-273.	2.5	25
8	CircRNAs Dysregulated in Juvenile Myelomonocytic Leukemia: CircMCTP1 Stands Out. Frontiers in Cell and Developmental Biology, 2020, 8, 613540.	3.7	12
9	Abstract 2541: MicroRNA-497~195 cluster suppresses acute lymphoblastic leukemia growth by targeting CCND3/CDK4 and inhibiting cell cycle progression. , 2020, , .		0
10	Incidence and Therapeutic Implications of Germline TP53 Mutations in Hypodiploid Childhood Acute Lymphoblastic Leukemia: A Retrospective Analysis of the Italian Cohort. Blood, 2020, 136, 43-44.	1.4	0
11	Simultaneous B and T cell acute lymphoblastic leukemias in zebrafish driven by transgenic MYC: implications for oncogenesis and lymphopoiesis. Leukemia, 2019, 33, 333-347.	7.2	28
12	Circular RNA differential expression in blood cell populations and exploration of circRNA deregulation in pediatric acute lymphoblastic leukemia. Scientific Reports, 2019, 9, 14670.	3.3	69
13	CircRNAs Are Here to Stay: A Perspective on the MLL Recombinome. Frontiers in Genetics, 2019, 10, 88.	2.3	19
14	ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells. Haematologica, 2019, 104, 533-545.	3.5	21
15	Pre-Clinical Efficacy of the Novel Kinase Inhibitor Nintedanib on PAX5 Fusion Genes in Pediatric Ph-like B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2019, 134, 745-745.	1.4	0
16	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell, 2018, 33, 937-948.e8.	16.8	142
17	Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients. Human Mutation, 2018, 39, 579-587.	2.5	16
18	AKR1C enzymes sustain therapy resistance in paediatric T-ALL. British Journal of Cancer, 2018, 118, 985-994.	6.4	31

#	Article	IF	Citations
19	Label-Free Detection of Microvesicles and Proteins by the Bundling of Gliding Microtubules. Nano Letters, 2018, 18, 117-123.	9.1	29
20	IKZF1^{plus} Defines a New Minimal Residual Diseaseâ€“Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 1240-1249.	1.6	194
21	The presence of mutated and deleted <scp>PTEN</scp> is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with <scp>AIEOP</scp>â€<scp>BFM ALL</scp> protocols. British Journal of Haematology, 2018, 182, 705-711.	2.5	30
22	Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL. Molecular Cancer Therapeutics, 2018, 17, 1705-1716.	4.1	18
23	Activin A, a Potential Key Factor of the Malignant Bone Marrow Niche, Enhances B-Cell Precursor-Acute Lymphoblastic Leukemic Cell Migratory and Invasive Properties. Blood, 2018, 132, 1296-1296.	1.4	1
24	Bone Marrow Mesenchymal Stromal Cells and Inflammation Contribute to ETV6-RUNX1+ Preleukemic Cells Persistence and DNA Damaging. Blood, 2018, 132, 3918-3918.	1.4	0
25	<scp>DNA</scp> methylation and targeted sequencing of methyltransferases family genes in canine acute myeloid leukaemia, modelling human myeloid leukaemia. Veterinary and Comparative Oncology, 2017, 15, 910-918.	1.8	12
26	Expression Profiling of Circulating Microvesicles Reveals Intercellular Transmission of Oncogenic Pathways. Molecular Cancer Research, 2017, 15, 683-695.	3.4	29
27	ETV6/RUNX1â€like acute lymphoblastic leukemia: A novel Bâ€cell precursor leukemia subtype associated with the CD27/CD44 immunophenotype. Genes Chromosomes and Cancer, 2017, 56, 608-616.	2.8	63
28	Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4030-E4039.	7.1	62
29	Clinical significance of recurrent copy number aberrations in Bâ€lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts. British Journal of Haematology, 2017, 178, 583-587.	2.5	23
30	Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor. Blood, 2017, 130, 643-654.	1.4	68
31	Aberrantly expressed TET1 in T-ALL regulates DNA repair and leukemic growth via maintenance of 5-hydroxymethylome and can be antagonized by the parp inhibitor Olaparib. Experimental Hematology, 2017, 53, S129-S130.	0.4	0
32	CirComPara: A Multiâ€Method Comparative Bioinformatics Pipeline to Detect and Study circRNAs from RNAâ€seq Data. Non-coding RNA, 2017, 3, 8.	2.6	41
33	High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia. Oncotarget, 2017, 8, 42398-42413.	1.8	19
34	Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. Oncotarget, 2016, 7, 13886-13901.	1.8	20
35	An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts. Cell Death and Disease, 2016, 7, e2047-e2047.	6.3	15
36	Role of CXCR4-mediated bone marrow colonization in CNS infiltration by T cell acute lymphoblastic leukemia. Journal of Leukocyte Biology, 2016, 99, 1077-1087.	3.3	41

#	Article	IF	Citations
37	LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia. Blood, 2016, 127, 1163-1172.	1.4	48
38	CircRNAs in hematopoiesis and hematological malignancies. Blood Cancer Journal, 2016, 6, e483-e483.	6.2	139
39	Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis. Scientific Reports, 2016, 6, 34449.	3.3	20
40	CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. Leukemia Research, 2016, 41, 36-42.	0.8	41
41	Sensing protein antigen and microvesicle analytes using high-capacity biopolymer nano-carriers. Analyst, The, 2016, 141, 836-846.	3.5	16
42	CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. Oncotarget, 2016, 7, 59260-59272.	1.8	24
43	Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group. Oncotarget, 2016, 7, 28914-28919.	1.8	21
44	TET1 Promotes Leukemic Growth in T-ALL Via Maintenance of 5-Hydroxymethylation Marks and Can be Antagonized By the PARP Inhibitor Olaparib. Blood, 2016, 128, 737-737.	1.4	0
45	Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica, 2015, 100, e229-e232.	3.5	29
46	LCKover-expression drives STAT5 oncogenic signaling inPAX5translocated BCP-ALL patients. Oncotarget, 2015, 6, 1569-1581.	1.8	17
47	Genomics and drug profiling of fatal TCF3-HLFâ˚positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nature Genetics, 2015, 47, 1020-1029.	21.4	190
48	Refinement of IKZF1 status in pediatric Philadelphia-positive acute lymphoblastic leukemia. Leukemia, 2015, 29, 2107-2110.	7.2	18
49	Role of the Histone Deacetylase Inhibitor Givinostat (ITF2357) in Treatment of CRLF2 Rearranged Acute Lymphoblastic Leukemia. Blood, 2015, 126, 2534-2534.	1.4	1
50	Migration of Acute Lymphoblastic Leukemia Cells into the Central Nervous System Is Regulated By VEGF. Blood, 2015, 126, 2634-2634.	1.4	4
51	Targeting Mutant p53 in Pediatric Acute Lymphoblastic Leukemia. Blood, 2015, 126, 903-903.	1.4	1
52	Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model. Oncotarget, 2015, 6, 1382-1395.	1.8	11
53	Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia. Human Molecular Genetics, 2014, 23, 590-601.	2.9	13
54	Notch3/Jagged1 Circuitry Reinforces Notch Signaling and Sustains T-ALL. Neoplasia, 2014, 16, 1007-1017.	5.3	45

#	Article	IF	Citations
55	Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nature Genetics, 2014, 46, 618-623.	21.4	117
56	Different outcomes of allogeneic hematopoietic stem cell transplant in a pair of twins affected by juvenile myelomonocytic leukemia. International Journal of Hematology, 2014, 99, 208-212.	1.6	7
57	IKZF1 status as a prognostic feature in BCR-ABL1â€“positive childhood ALL. Blood, 2014, 123, 1691-1698.	1.4	129
58	Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations. Blood, 2014, 124, 3577-3582.	1.4	49
59	The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1plus) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment. Blood, 2014, 124, 131-131.	1.4	4
60	Epigenetic Silencing of TFPI-2 in Canine Diffuse Large B-Cell Lymphoma. PLoS ONE, 2014, 9, e92707.	2.5	33
61	Array-Based Comparative Genomic Hybridization Analysis Reveals Chromosomal Copy Number Aberrations Associated with Clinical Outcome in Canine Diffuse Large B-Cell Lymphoma. PLoS ONE, 2014, 9, e111817.	2.5	25
62	Low PKCÎ± expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome. Oncotarget, 2014, 5, 5234-5245.	1.8	20
63	Abstract 433: Triplication of HMGN1 promotes B cell acute lymphoblastic leukemia (B-ALL) through suppression of H3K27me3. , 2014, , .		0
64	Refinement of IKZF1 Genomic Status in Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3785-3785.	1.4	0
65	Effective in Vivo Targeting of BCP-ALL in a NOD/SCID/huALL Mouse Model By CD70 Directed Immunotherapy. Blood, 2014, 124, 970-970.	1.4	0
66	Subunit a of Coagulation Factor XIII As a New Biomarker in Childhood Acute Lymphoblastic Leukemia?. Blood, 2014, 124, 5346-5346.	1.4	1
67	Secondary Mutations of JAK3 and SETBP1 in Juvenile Myelomonocytic Leukemia and Their Propagating Capacity; A Report from the AIEOP Study Group. Blood, 2014, 124, 4625-4625.	1.4	0
68	Wnt activation promotes neuronal differentiation of Glioblastoma. Cell Death and Disease, 2013, 4, e500-e500.	6.3	89
69	Ultrafast molecular motor driven nanoseparation and biosensing. Biosensors and Bioelectronics, 2013, 48, 145-152.	10.1	37
70	The MLL recombinome of acute leukemias in 2013. Leukemia, 2013, 27, 2165-2176.	7.2	393
71	Sample solution constraints on motor-driven diagnostic nanodevices. Lab on A Chip, 2013, 13, 866.	6.0	29
72	AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells. Leukemia, 2013, 27, 1019-1027.	7.2	40

#	Article	IF	Citations
73	Linking genomic lesions with minimal residual disease improves prognostic stratification in children with T-cell acute lymphoblastic leukaemia. Leukemia Research, 2013, 37, 928-935.	0.8	16
74	What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?. Haematologica, 2013, 98, 1226-1231.	3.5	65
75	PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5. Leukemia, 2013, 27, 992-995.	7.2	24
76	Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia. Blood Cancer Journal, 2013, 3, e160-e160.	6.2	35
77	New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia. Blood, 2013, 121, 5064-5067.	1.4	53
78	Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica, 2013, 98, 1702-1710.	3.5	121
79	Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia". Haematologica, 2013, 98, e164-e165.	3.5	16
80	Copy Number Variations and IKZF1 Mutations In Pediatric CML. Blood, 2013, 122, 1473-1473.	1.4	2
81	Philadelphia-Like Signature In Childhood Acute Lymphoblastic Leukemia: The AIEOP Experience. Blood, 2013, 122, 353-353.	1.4	9
82	The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. Blood, 2013, 122, 743-743.	1.4	6
83	PAX5 Fusion Genes Activate The STAT5 Signaling Pathway Through Lck Over-Expression. Blood, 2013, 122, 3738-3738.	1.4	0
84	Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia. Leukemia, 2012, 26, 902-909.	7.2	106
85	Mesenchymal stem cells from Shwachmanâ€“Diamond syndrome patients display normal functions and do not contribute to hematological defects. Blood Cancer Journal, 2012, 2, e94-e94.	6.2	17
86	Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. British Journal of Haematology, 2012, 158, 772-777.	2.5	39
87	Gene expression signatures of pediatric myelodysplastic syndromes are associated with risk of evolution into acute myeloid leukemia. Leukemia, 2012, 26, 1717-1719.	7.2	6
88	Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia, 2012, 26, 2245-2253.	7.2	96
89	Antibodies Covalently Immobilized on Actin Filaments for Fast Myosin Driven Analyte Transport. PLoS ONE, 2012, 7, e46298.	2.5	22
90	Microvesicles Transcripts As Hallmark and Vector From Leukemic Parental Cells. Blood, 2012, 120, 1459-1459.	1.4	0

#	Article	IF	Citations
91	Mosaic Distribution of RAS Pathway Mutated and Non Mutated Cells in Bone Marrow of Juvenile Myelomonocytic Leukemia.. Blood, 2012, 120, 2818-2818.	1.4	0
92	CI-FISH, GEP, and SNPs Correlate Genomic Categories with Risk Stratification in Children with T-ALL.. Blood, 2012, 120, 2485-2485.	1.4	0
93	MLLT10 Gene Promiscuity Unravels Involvement of RNA Processing Genes in Pediatric T-Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1431-1431.	1.4	0
94	Fine Tuning of Surface CRLF2 Expression and Its Associated Signalling Profile in Childhood B Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1409-1409.	1.4	9
95	Gain-of-function mutations in interleukin-7 receptor-Î± (IL7R) in childhood acute lymphoblastic leukemias. Journal of Experimental Medicine, 2011, 208, 901-908.	8.5	307
96	Non-medical applications of non-invasive prenatal diagnosis: Ethical issues. Forensic Science International: Genetics Supplement Series, 2011, 3, e554-e555.	0.3	2
97	DNA methyltransferase 3a hot-spot locus is not mutated in pediatric patients affected by acute myeloid or T-cell acute lymphoblastic leukemia: an Italian study. Haematologica, 2011, 96, 1886-1887.	3.5	11
98	Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia. Blood, 2011, 117, 4746-4758.	1.4	84
99	MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study. Leukemia, 2011, 25, 560-563.	7.2	31
100	Early Relapse in ALL Is Identified by Time to Leukemia in NOD/SCID Mice and Is Characterized by a Gene Signature Involving Survival Pathways. Cancer Cell, 2011, 19, 206-217.	16.8	80
101	The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia, 2011, 25, 1840-1848.	7.2	96
102	Gain-of-function mutations in interleukin-7 receptor-Î± (IL7R) in childhood acute lymphoblastic leukemias. Journal of Experimental Medicine, 2011, 208, 1333-1333.	8.5	6
103	Poor Prognosis for IKZF1 Intra-Gene Deletions in Pediatric Phâ' B-Cell Precursor Acute Lymphoblastic Leukemia,. Blood, 2011, 118, 3518-3518.	1.4	1
104	High Risk Acute Lymphoblastic Leukemia with Rapid NOD/SCID Engraftment Is Characterized by High Protein Expression of CYCLIN B, Beta-CATENIN, ANNEXIN I and Decreased PKC Alpha Activation. Blood, 2011, 118, 1457-1457.	1.4	0
105	Evolution of Sub-Clones with KRAS Mutations In Pediatric Patients with MLL-AF4 Rearrangements. Blood, 2011, 118, 2454-2454.	1.4	6
106	Specific Circulating Microvesicles (cMVs) Populations in Paediatric ALL. Blood, 2011, 118, 933-933.	1.4	1
107	Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood, 2010, 115, 1006-1017.	1.4	305
108	PTPN11 mutations in childhood acute lymphoblastic leukemia occur as a secondary event associated with high hyperdiploidy. Leukemia, 2010, 24, 232-235.	7.2	17

#	Article	IF	Citations
109	Functional Protein Network Activation Mapping Reveals New Potential Molecular Drug Targets for Poor Prognosis Pediatric BCP-ALL. PLoS ONE, 2010, 5, e13552.	2.5	42
110	Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group. Journal of Clinical Oncology, 2010, 28, 2529-2537.	1.6	567
111	Gene Expressionâ€"Based Classification As an Independent Predictor of Clinical Outcome in Juvenile Myelomonocytic Leukemia. Journal of Clinical Oncology, 2010, 28, 1919-1927.	1.6	74
112	STAT5 Phosphorylation Status by Flow Cytometry Is a Rapid and Reliable Tool for Diagnosis and Follow-up of Juvenile Myelomonocytic Leukemia. Blood, 2010, 116, 2751-2751.	1.4	0
113	Molecular Mechanisms of HIF-1Î± Modulation Induced by Oxygen Tension and BMP2 in Glioblastoma Derived Cells. PLoS ONE, 2009, 4, e6206.	2.5	45
114	MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures. BMC Medical Genomics, 2009, 2, 36.	1.5	35
115	New insights to the MLL recombinome of acute leukemias. Leukemia, 2009, 23, 1490-1499.	7.2	363
116	Hypoxia and HIF1Î± Repress the Differentiative Effects of BMPs in High-Grade Glioma. Stem Cells, 2009, 27, 7-17.	3.2	100
117	Two independent gene signatures in pediatric t(4;11) acute lymphoblastic leukemia patients. European Journal of Haematology, 2009, 83, 406-419.	2.2	51
118	DOWN'S Syndrome Acute Lymphoblastic LEUKEMIA: A HIGHLY Heterogeneous DISEASE DRIVEN by an Aberrant CRLF2/JAK2 Cooperation â€" A REPORT FROM the Ibfm-STUDY GROUP.. Blood, 2009, 114, 11-11.	1.4	2
119	Reverse Phase Protein Assay (RPPA) Defines Specific Patterns in Childhood Acute Lymphoblastic Leukemia (ALL). Blood, 2008, 112, 2510-2510.	1.4	1
120	The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia: Final Report on 3252 Cases from the International MILE Study Group. Blood, 2008, 112, 753-753.	1.4	10
121	Time to Leukemia (TTL) in NOD/SCID Mice Determines Patient Outcome and Is Characterized by a 5 Genes Signature Associated with Relapse. Blood, 2008, 112, 755-755.	1.4	0
122	Hepatocyte Growth Factor Receptor c-MET Is Associated with FAS and When Activated Enhances Drug-induced Apoptosis in Pediatric B Acute Lymphoblastic Leukemia with TEL-AML1 Translocation. Journal of Biological Chemistry, 2007, 282, 29384-29393.	3.4	17
123	New data on robustness of gene expression signatures in leukemia: comparison of three distinct total RNA preparation procedures. BMC Genomics, 2007, 8, 188.	2.8	12
124	Down-regulation of DLX3 expression in MLL-AF4 childhood lymphoblastic leukemias is mediated by promoter region hypermethylation. Oncology Reports, 2007, 18, 417-23.	2.6	15
125	Immunophenotype signature as a tool to define prognostic subgroups in childhood acute myeloid leukemia. Leukemia, 2006, 20, 888-891.	7.2	5
126	Post-transcriptional Silencing and Functional Characterization of the Drosophila melanogaster Homolog of Human Surf1. Genetics, 2006, 172, 229-241.	2.9	42

#	Article	IF	Citations
127	New Data on Robustness of Gene Expression Signatures in Leukemia: Comparison of Three Distinct Total RNA Preparation Procedures.. Blood, 2006, 108, 4288-4288.	1.4	6
128	Validation by RQ-PCR and flow cytometry of alpha-defensin1-3 (DEFA1-3) overexpression in relapsed and refractory acute lymphoblastic leukemia. Oncology Reports, 2006, 15, 341-6.	2.6	2
129	The effects of siRNA-mediated inhibition of E2A-PBX1 on EB-1 and Wnt16b expression in the 697 pre-B leukemia cell line. Haematologica, 2006, 91, 765-71.	3.5	19
130	Drosophila CAKI/CMG Protein, a Homolog of Human CASK, Is Essential for Regulation of Neurotransmitter Vesicle Release. Journal of Neurophysiology, 2005, 94, 1074-1083.	1.8	41
131	A leukemia-enriched cDNA microarray platform identifies new transcripts with relevance to the biology of pediatric acute lymphoblastic leukemia. Haematologica, 2005, 90, 890-8.	3.5	26
132	Acute Leukemia Subclassification: A Marker Protein Expression Perspective. Hematology, 2004, 9, 165-170.	1.5	6
133	Muscle Plasticity and High Throughput Gene Expression Studies. Journal of Muscle Research and Cell Motility, 2004, 25, 231-234.	2.0	3
134	Computational analysis of flow-cytometry antigen expression profiles in childhood acute lymphoblastic leukemia: an MLL/AF4 identification. Leukemia, 2003, 17, 1557-1565.	7.2	49
135	Skeletal muscle fibre type specification during embryonic development. Journal of Muscle Research and Cell Motility, 2002, 23, 65-69.	2.0	27
136	Teleost Yolk Cell Function On Blastoderm Differentiation and Morphogenesis. Animal Biology, 2000, 50, 37-51.	0.4	1
137	TELEOST YOLK CELL FUNCTION ON BLASTODERM DIFFERENTIATION AND MORPHOGENESIS. Animal Biology, 2000, 50, 37-51.	0.4	4
138	Zebrafish CTH1, a C3H zinc finger protein, is expressed in ovarian oocytes and embryos. Development Genes and Evolution, 1999, 209, 443-446.	0.9	17
139	The carp homeobox gene Ovx1 shows early expression during gastrulation and subsequently in the vagal lobe, the facial lobe and the ventral telencephalon. Development Genes and Evolution, 1998, 208, 56-59.	0.9	3
140	Blastoderm Structure, Cell Migration and Formation of the Embryonic Shield During Gastrulation in the Carp (Cyprinus carpio); a Scanning Electron Microscopic Study. European Journal of Morphology, 1998, 36, 65-75.	0.8	2
141	Isolation of carp cDNA clones, representing developmentally-regulated genes, using a subtractive-hybridization strategy. Roux's Archives of Developmental Biology, 1996, 205, 460-467.	1.2	3
142	Expression of carp-cdx1, a caudal homolog, in embryos of the carp, Cyprinus carpio. Roux's Archives of Developmental Biology, 1995, 204, 369-377.	1.2	13
143	Gastrulation in Cyprinids: Morphogenesis and Gene Expression. Animal Biology, 1995, 46, 115-133.	0.4	1
144	Mesoderm differentiation in explants of carp embryos. Roux's Archives of Developmental Biology, 1994, 204, 20-29.	1.2	1

#	Article	IF	Citations
145	The segregation of inner and outer cells in porcine embryos follows a different pattern compared to the segregation in mouse embryos. Roux's Archives of Developmental Biology, 1993, 203, 113-116.	1.2	10
146	DNA probes to repetitive sequences for the analysis of porcine genomic DNA with reference to DNA methylation. Theriogenology, 1993, 39, 1313-1320.	2.1	2
147	Embryonic development in the pig up to the 64-cell stage, with reference to DNA replication and cell cycle times from the third cleavage division. Theriogenology, 1993, 39, 919-928.	2.1	3
148	Differential susceptibility of early steps in carp (Cyrinus carpio) development to ?-amanitin. Roux's Archives of Developmental Biology, 1992, 202, 61-65.	1.2	10
149	Myosin isoforms in hindlimb muscles of normal and dystrophic (ReJ129 dy/sol;dy) mice. Muscle and Nerve, 1992, 15, 199-208.	2.2	16
150	Development of immunohistochemical characteristics of intrafusal fibres in normal and de-efferented rat muscle spindles. Histochemistry, 1982, 74, 355-366.	1.9	29
151	Immunohistochemical differences in myosin composition among intrafusal muscle fibres. Histochemistry, 1981, 73, 65-74.	1.9	27
152	Differentiation of muscle fiber types in the teleost Brachydanio rerio. Anatomy and Embryology, 1978, 153, 137-155.	1.5	125